Sickle cell disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• G6PD 0
• NLRP3 0
• APOL1 0
• CD19 3
• BTK 0
• FGFR 0
• NRF2 0
• SGLT2 1
• CFTR 1
• CXCR4 0
• DMD 1
• GLP-1 0
• HDAC 1
• HMGB1 0
• HTT 1
• JAK 0
• NF1 1
• SMN1 1

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 726 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease

  NCT07436767· Institute of Hematology & Blood Diseases Hospital, China· Updated 5 Nov 2026

  “Difficulty identifying eligible patients.”Registry text, quoted unchanged. Source

• Terminated

  Open-Label Extension Study to Pioneer Study 6058-SCD-101

  NCT07401823· Fulcrum Therapeutics· Updated 28 Oct 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease

  NCT03279094· City of Hope Medical Center· Updated 26 Oct 2026

  “Closed to accrual - no accruals in CTMS”Registry text, quoted unchanged. Source

• Withdrawn

  Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

  NCT06979492· Emory University· Updated 19 Oct 2026

  “The study was withdrawn due to no enrollment”Registry text, quoted unchanged. Source

• Terminated

  AB1 in Adult Patients With Sickle Cell Disease (SCD)

  NCT05261711· Nirmish Shah· Updated 15 Oct 2026

  “Study is terminated prior to its planned completion as anticipated by the protocol due to enrollment completion. Data clean up and analysis is being performed.”Registry text, quoted unchanged. Source

• Withdrawn

  Biotin-Acridine Red Cell Exchange Kinetics

  NCT07155031· Cerus Corporation· Updated 22 Sept 2026

  “This study has been suspended due to a lack of funding. The protocol will be reconsidered within the next 6-12 months if/as funding becomes available.”Registry text, quoted unchanged. Source

• Withdrawn

  Testing the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention

  NCT06562439· Washington University School of Medicine· Updated 25 Aug 2026

  “not a clinical trial”Registry text, quoted unchanged. Source

• Terminated

  Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

  NCT07431398· Fulcrum Therapeutics· Updated 18 Jun 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Siplizumab for Sickle Cell Disease Transplant

  NCT06078696· Columbia University· Updated 10 Jun 2026

  “Closed by the industry collaborator”Registry text, quoted unchanged. Source

• Terminated

  GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

  NCT05632354· Pfizer· Updated 19 Mar 2026

  “Study terminated as data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

  NCT06665997· University of Pennsylvania· Source

• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· CSL Behring· Source

• A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

  NCT06546670· Novartis Pharmaceuticals· Source

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

  NCT06975865· Sanofi· Source

• Gene Editing For Sickle Cell Disease

  NCT06506461· St. Jude Children's Research Hospital· Source

• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  NCT06439082· Novartis Pharmaceuticals· Source

• Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

  NCT03814746· Novartis Pharmaceuticals· Source

• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· CSL Behring· Source

• Cooperative Assessment of Late Effects for SCD Curative Therapies

  NCT05153967· Vanderbilt University Medical Center· Source

• Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire

  NCT07488520· Swiss Tropical & Public Health Institute· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• CRISPR-Cas Systems 15
• Gene Expression Profiling 7
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 2
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 2
• Magnetic Resonance Imaging 21
• Machine Learning 5
• Deep Learning 3
• Cohort Studies 19
• Genome-Wide Association Study 5

• Immune Imbalance in Sickle Cell Anemia: Flow Cytometric Insights Into Regulatory T Cells and Neutrophil Dynamics.

  J Clin Lab Anal, Apr 2026

• Defining the Role of Marginal Zone B Cells in RBC Alloimmunization.

  Methods Mol Biol, Jan 2026

• Analysis of Biotinylated Red Blood Cells Following Transfusion.

  Methods Mol Biol, Jan 2026

• Cytokine and immune cell interaction in immune-inflammatory response during crisis event in sickle cell disease.

  Afr Health Sci, Mar 2025

• Decreased expression of CD73 (ecto-5'-nucleotidase) in the CD8+ subset is associated with zinc deficiency in human patients.

  J Lab Clin Med, Aug 1997

See which targets of this disease your abstract mentions, and go to the people working on them.